Cargando…

Spotlight on brimonidine topical gel 0.33% for facial erythema of rosacea: safety, efficacy, and patient acceptability

BACKGROUND: Brimonidine tartrate is a highly selective alpha 2 agonist that induces direct vasoconstriction of small arteries and veins, thereby reducing vasodilation and edema. OBJECTIVE: To review the current literature regarding the safety, efficacy, and patient acceptability of brimonidine 0.33%...

Descripción completa

Detalles Bibliográficos
Autores principales: Anderson, Michael S, Nadkarni, Anish, Cardwell, Leah A, Alinia, Hossein, Feldman, Steven R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5505675/
https://www.ncbi.nlm.nih.gov/pubmed/28740369
http://dx.doi.org/10.2147/PPA.S115708
_version_ 1783249459463847936
author Anderson, Michael S
Nadkarni, Anish
Cardwell, Leah A
Alinia, Hossein
Feldman, Steven R
author_facet Anderson, Michael S
Nadkarni, Anish
Cardwell, Leah A
Alinia, Hossein
Feldman, Steven R
author_sort Anderson, Michael S
collection PubMed
description BACKGROUND: Brimonidine tartrate is a highly selective alpha 2 agonist that induces direct vasoconstriction of small arteries and veins, thereby reducing vasodilation and edema. OBJECTIVE: To review the current literature regarding the safety, efficacy, and patient acceptability of brimonidine 0.33% gel. METHODS: A PubMed search was performed using the terms brimonidine 0.33% gel, rosacea, safety, efficacy, and acceptability. Peer-reviewed clinical trials and case reports from 2012 to 2016 were screened for inclusion of safety, efficacy, and/or patient acceptability data. RESULTS: Brimonidine topical gel 0.33% is associated with mild, transient skin-related adverse reactions. Efficacy may be achieved within 30 minutes of administration with maximal reductions in erythema 3–6 hours after administration. Patient satisfaction with use of brimonidine topical gel is superior to vehicle gel for facial appearance, treatment effect, facial redness, and daily control of facial redness. LIMITATIONS: Studies were typically limited to 1-year follow-up. Only one study has examined the use of brimonidine topical gel in combination with other rosacea and acne medications. DISCUSSION: Brimonidine topical gel 0.33% is a safe, effective, and patient-accepted treatment for facial erythema of rosacea.
format Online
Article
Text
id pubmed-5505675
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-55056752017-07-24 Spotlight on brimonidine topical gel 0.33% for facial erythema of rosacea: safety, efficacy, and patient acceptability Anderson, Michael S Nadkarni, Anish Cardwell, Leah A Alinia, Hossein Feldman, Steven R Patient Prefer Adherence Review BACKGROUND: Brimonidine tartrate is a highly selective alpha 2 agonist that induces direct vasoconstriction of small arteries and veins, thereby reducing vasodilation and edema. OBJECTIVE: To review the current literature regarding the safety, efficacy, and patient acceptability of brimonidine 0.33% gel. METHODS: A PubMed search was performed using the terms brimonidine 0.33% gel, rosacea, safety, efficacy, and acceptability. Peer-reviewed clinical trials and case reports from 2012 to 2016 were screened for inclusion of safety, efficacy, and/or patient acceptability data. RESULTS: Brimonidine topical gel 0.33% is associated with mild, transient skin-related adverse reactions. Efficacy may be achieved within 30 minutes of administration with maximal reductions in erythema 3–6 hours after administration. Patient satisfaction with use of brimonidine topical gel is superior to vehicle gel for facial appearance, treatment effect, facial redness, and daily control of facial redness. LIMITATIONS: Studies were typically limited to 1-year follow-up. Only one study has examined the use of brimonidine topical gel in combination with other rosacea and acne medications. DISCUSSION: Brimonidine topical gel 0.33% is a safe, effective, and patient-accepted treatment for facial erythema of rosacea. Dove Medical Press 2017-07-06 /pmc/articles/PMC5505675/ /pubmed/28740369 http://dx.doi.org/10.2147/PPA.S115708 Text en © 2017 Anderson et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Review
Anderson, Michael S
Nadkarni, Anish
Cardwell, Leah A
Alinia, Hossein
Feldman, Steven R
Spotlight on brimonidine topical gel 0.33% for facial erythema of rosacea: safety, efficacy, and patient acceptability
title Spotlight on brimonidine topical gel 0.33% for facial erythema of rosacea: safety, efficacy, and patient acceptability
title_full Spotlight on brimonidine topical gel 0.33% for facial erythema of rosacea: safety, efficacy, and patient acceptability
title_fullStr Spotlight on brimonidine topical gel 0.33% for facial erythema of rosacea: safety, efficacy, and patient acceptability
title_full_unstemmed Spotlight on brimonidine topical gel 0.33% for facial erythema of rosacea: safety, efficacy, and patient acceptability
title_short Spotlight on brimonidine topical gel 0.33% for facial erythema of rosacea: safety, efficacy, and patient acceptability
title_sort spotlight on brimonidine topical gel 0.33% for facial erythema of rosacea: safety, efficacy, and patient acceptability
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5505675/
https://www.ncbi.nlm.nih.gov/pubmed/28740369
http://dx.doi.org/10.2147/PPA.S115708
work_keys_str_mv AT andersonmichaels spotlightonbrimonidinetopicalgel033forfacialerythemaofrosaceasafetyefficacyandpatientacceptability
AT nadkarnianish spotlightonbrimonidinetopicalgel033forfacialerythemaofrosaceasafetyefficacyandpatientacceptability
AT cardwellleaha spotlightonbrimonidinetopicalgel033forfacialerythemaofrosaceasafetyefficacyandpatientacceptability
AT aliniahossein spotlightonbrimonidinetopicalgel033forfacialerythemaofrosaceasafetyefficacyandpatientacceptability
AT feldmanstevenr spotlightonbrimonidinetopicalgel033forfacialerythemaofrosaceasafetyefficacyandpatientacceptability